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Abstract
: Thyroid function is closely related to leptin's secretion by the adipose tissue. In states of leptin-
deficiency, the circadian rhythm of TSH is altered, leading to central hypothyroidism in animal
models. In humans, central hypothyroidism has also been described in rare cases of congenital
leptin deficiency. However, the thyroid phenotype in these cases is heterogeneous, with the
occurrence of central hypothyroidism in a minority of cases. Here we describe thyroid function in
four leptin-deficient humans (2 males aged 5 and 27, and 2 females aged 35 and 40), before and
during leptin replacement with recombinant human methionyl leptin (r-metHuLeptin). The child
was evaluated for four years, and the adults, for eight years. In addition, the adults were submitted
to a brief withdrawal of leptin during six weeks in the sixth year. Our results show that, regardless
of leptin replacement, our leptin-deficient patients have normal thyroid function. In spite of having
an important role in regulating the hypothalamic-pituitary-thyroidal axis, leptin is not required for
normal thyroid function.
Trial Registration: ClinicalTrials.gov Identifiers: NCT00659828 and NCT00657605
Findings
There is evidence that the hypothalamic-pituitary-thyroi-
dal axis is regulated, at least in part, by leptin. This pro-
vides an important interface between adiposity, regulated
by leptin, and metabolic rate, regulated by thyroid hor-
mones. The mechanisms underlying the connection
between adipose signals and energy expenditure include
the regulation of the synthesis and secretion of TRH (thy-
rotropin releasing hormone) by leptin, through the medi-
ation of input from the arcuate nucleus to the TRH
neurons in the paraventricular nucleus (PVN) [1]. In addi-
tion, the thyroid axis is also indirectly regulated by leptin's
actions on the melanocortin pathway, as alpha-MSH
(melanocyte stimulating hormone) stimulates and AgRP
(agouti-related protein) blocks TRH release [2]. Further-
more, leptin has direct effects on TRH neurons, regulating
its synthesis not only by up-regulating the expression of
the proTRH gene in the PVN [3] and by influencing the
feedback regulation of the TRH-secreting neurons by thy-
roid hormones, but also by increasing promoter activities
of the prohormone convertases PC1/3 and PC2, essential
for the activation of TRH from proTRH [4].
In leptin-deficient humans, different thyroid phenotypes
have been reported. In three children of Pakistani origin,
thyroid function tests were within the normal range
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TSH (mU/L) A 3.8 * 4.5 4.17 * * * *
B 0.93 1.1 * 0.64 1.68 1.26 0.68 1.38
C 1.5 * * * 1.09 1.61 1.27 1.0
D 2.4 0.88 * 0.47 0.83 1.15 1.52 1.23
Total T4
(μg/dl)
A 5.4 * 8.8 * * * * *
B 6.9 6.9 * 9.1 7.5 7.6 * *
C 8.4 * * * 8.0 8.4 * *
D 5.2 7.9 * 10.9 7.5 6.5 * *
Total T3
(ng/dl)
A * * * * * * * *
B 114 112 167 121 121 * * *
C 118 * * * 112 118 * *
D 76 125 * 110 122 106 * *
Free T4
(ng/dl)
A 1.3 * 1.2 1.49 * * * *
B * * * * 1.0 * 0.9 1.34
C * * * * 1.1 1.3 0.8 1.47
D * * * * 1.1 1.0 0.73 1.16
BMI (kg/m2) A 39.6 24.8 23.8 22.6 * * * *
B 51.4 24.5 22.6 23.7 23.3 26.7 25.8 25.4
C 46.7 26.0 26.0 25.0 26.7 29.0 30.3 32.2
D 55.4 35.0 28.0 31.7 33.3 36.2 32.5 36.5
* Not available
Reference ranges: TSH: 0.40-4.0 mU/L; total T4: 4.5-12.5 μg/dl; total T3: 75-178 ng/dl; free T4: 0.7-2.1 ng/dl
before the start of recombinant human methionyl leptin
(r-metHuLeptin) therapy, with a rise in free T4 (fT4)
thereafter in all children, and an increase in T3 in the two
youngest [5]. In another child, also of Pakistani origin,
subclinical hypothyroidism was diagnosed before treat-
ment, with high TSH and normal T4 levels [6]. Treatment
with levothyroxine (LT4) was initiated before r-metH-
uLeptin, with a decrease in TSH levels. After the initiation
of r-metHuLeptin, fT4 levels increased above the upper
limit of the reference range, leading to the interruption of
LT4 therapy. While on r-metHuLeptin, off LT4, thyroid
function and TSH response to TRH were normal, which
gives further support to the hypothesis that the hypotha-
lamic-pituitary-thyroidal is regulated by leptin.Page 2 of 4
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Thyroid Research 2009, 2:11 http://www.thyroidresearchjournal.com/content/2/1/11Table 2: Clinical and biochemical parameters of the Pakistani and Turkish leptin-deficient patients, before treatment with r-
metHuLeptin.
Pakistani children Turkish patients* Turkish child
BMI (kg/m2) 41.3 ± 5.5 48.3 ± 6.8 39.6
Insulin (μIU/ml) 20.9 ± 11.5 9.3 ± 8.0 21
Glucose (mg/dl) 77.4 ± 11.4 97.2 ± 23.1 79
HOMA-IR 3.6 ± 1.9 2.1 ± 1.5 4.1
Total cholesterol (mg/dl) 181.2 ± 18.1 149.7 ± 29.5 166
HDL-c (mg/dl) 37.3 ± 10.1 32.8 ± 4.2 36
LDL-c (mg/dl) 85.6 ± 33.7 83.5 ± 16.9 87
Triglycerides (mg/dl) 162.2 ± 60.0 166.7 ± 78.1 216
*including the leptin-deficient child
We would like to document here that the phenotype of
leptin-deficient patients is highly heterogeneous, by
reporting the findings on thyroid function in leptin-defi-
cient patients of Turkish origin. We have been studying
three adults (1 male and 2 females) and one boy from a
highly consanguineous Turkish family. Those patients
have a nonconservative missense leptin gene mutation
(cysteine-to-threonine in codon 105), which renders
them leptin-deficient. We previously described the effects
of treatment with r-metHuLeptin, started at ages 5 (male
patient A) [7], 27 (male patient B), 35 and 40 (female
patients C and D, respectively) [8].
As opposed to the findings in one child of Pakistani ori-
gin, our leptin-deficient boy (A) had normal thyroid func-
tion before, two and four years after the initiation of r-
metHuLeptin. In addition, we have not observed an
increase in fT4 or T3 levels after the initiation of r-metH-
uLeptin (Table 1).
Similarly, the leptin-deficient adults also have normal thy-
roid function, both before and after the initiation of r-
metHuLeptin. Six years after the initiation of treatment, a
brief withdrawal of leptin during six weeks was under-
taken. No significant changes in thyroid hormones were
observed (Table 1). In spite of having normal thyroid
function, we have previously shown that the absence of
leptin disorganizes the circadian rhythm of TSH [9]. In
addition, levels of anti-thyroid antibodies were normal in
our patients, at all times.
Based on our data we conclude that in spite of having an
important role in regulating the hypothalamic-pituitary-
thyroidal axis, leptin is not required for normal thyroid
function. Why does leptin deficiency cause different thy-
roid phenotypes? Leptin is truly pleiotropic, with multiple
effects that can directly or indirectly affect thyroid func-
tion. Therefore, thyroid dysfunction, in a leptin-deficient
state, may exist due to diverse combinations of factors that
may vary across patients. In addition, age may be an
important determinant of thyroid dysfunction, as only the
youngest child showed laboratorial alterations related to
thyroid function. It is important to note that not only the
thyroid phenotype is heterogeneous among leptin-defi-
cient patients. In comparison with the patients of Paki-
stani origin, our patients had higher body mass index
(BMI), but lower insulin levels and insulin resistance
index (HOMA-IR), as illustrated in Table 2. This heteroge-
neity was observed even among the Turkish patients for
several parameters. In addition, the therapeutic regimen
was slightly different in both groups of patients, regarding
the time of administration of leptin (in the morning vs. in
the evening for our patients - mimicking leptin's circadian
rhythm). Nevertheless, in both protocols, dose was
adjusted based on clinical response. That heterogeneous
phenotype may be explained by several factors, such as a
different concentration of leptin soluble receptor, leading
to variations in free leptin levels. So far, the molecular
mechanisms by which different mutations in the leptin
gene lead to the presence or absence of thyroid dysfunc-
tion is unknown.
The multidirectional action of leptin in thyroid axis
should also be taken into account. Thyroid hormones can
stimulate the transcription of leptin gene through adren-
ergic effects. Although endogenous hyperthyroidism can
lead to higher leptin levels, short-term treatment does not
change leptinemia [10], neither does the induction of
hyperthyroid states in healthy males [11]. Another study
showed that hypothyroid patients have lower leptinemia
[12]. In our study, since all patients were euthyroid, this
multidirectional action does not apply.
In conclusion, we show here that thyroid dysfunction is
not a constant in leptin deficiency. The identification of
factors that lead to hypothyroidism in some, but not all,
leptin-deficient patients will provide better understanding
of the roles of leptin on the hypothalamic-pituitary-thy-
roidal axis. New insight on the interaction between leptin
and thyroid function will be gained from future studiesPage 3 of 4
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aimed at identifying the factors that protect our leptin-
deficient patients from clinical thyroid dysfunction, even
in the presence of an abnormal circadian rhythm of TSH.
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